amiloride Side Effects
Also known as: Midamor
Analysis of 834 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
834
Death-Related
62
7.4% of reports
Hospitalizations
384
46.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 62 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| RENAL FAILURE | 8 |
| DEATH | 7 |
| DIARRHOEA | 7 |
| CARDIAC ARREST | 6 |
| HYPOTENSION | 6 |
| ABDOMINAL PAIN | 5 |
| CARDIAC FAILURE | 5 |
| CARDIAC FAILURE CONGESTIVE | 5 |
| DYSPNOEA | 5 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 5 |
| LOSS OF CONSCIOUSNESS | 5 |
| DRUG INTERACTION | 4 |
| MULTI-ORGAN FAILURE | 4 |
| MYOCARDIAL INFARCTION | 4 |
| NAUSEA | 4 |
| NEUTROPENIA | 4 |
| PULMONARY HYPERTENSION | 4 |
| PYREXIA | 4 |
| SEPSIS | 4 |
| ASTHENIA | 3 |
Reactions in Hospitalization Reports
Top reactions in 384 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DIARRHOEA | 35 |
| HYPERKALAEMIA | 25 |
| RENAL FAILURE ACUTE | 25 |
| NAUSEA | 24 |
| DYSPNOEA | 23 |
| OFF LABEL USE | 23 |
| PYREXIA | 23 |
| VOMITING | 22 |
| ASTHENIA | 20 |
| ANAEMIA | 19 |
| HYPONATRAEMIA | 19 |
| DEHYDRATION | 17 |
| MALAISE | 17 |
| ABDOMINAL PAIN | 16 |
| ACUTE KIDNEY INJURY | 14 |
| HYPOKALAEMIA | 14 |
| SOMNOLENCE | 14 |
| CONFUSIONAL STATE | 13 |
| DRUG INTERACTION | 13 |
| FALL | 13 |
Nearby — Related Medications
What the FAERS Data Reveals About amiloride Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 834 voluntary reports linked to amiloride and its brand equivalents (Midamor), spanning 2004 through 2025. Of those, 62 (7.4%) listed death as an outcome and 384 (46.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 44% male; age distribution skews toward 45-64, with 183 reports in that bracket. The single most reported reaction is dyspnoea with 69 submissions, followed by diarrhoea and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.